Show simple item record

dc.contributor.authorMena, Álvaro
dc.contributor.authorCid-Silva, Purificación
dc.contributor.authorDueñas, Carlos
dc.contributor.authorGarcinuño, María Ángeles
dc.contributor.authorLorenzo, Juan Francisco
dc.contributor.authorMargusino-Framiñán, Luis
dc.contributor.authorQuiñones, Marina
dc.contributor.authorGrande, Carmen
dc.contributor.authorRodríguez-Osorio, Iria
dc.contributor.authorCastro-Iglesias, Ángeles
dc.date.accessioned2019-01-17T09:09:59Z
dc.date.issued2019-01-03
dc.identifier.citationMena Á, Cid P, Dueñas C, et al. Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy. HIV Clin Trials. 2018; 19(5): 197-201es_ES
dc.identifier.issn1528-4336
dc.identifier.urihttp://hdl.handle.net/2183/21598
dc.description.abstract[Abstract] OBJECTIVES: Darunavir/ritonavir (DRV/r) in mono or dual therapy has proven efficacy in selected patients. The aim of this study was to evaluate the efficacy of switching from DRV/r to DRV/cobicistat (DRV/c) in patients under mono or dual therapy. METHODS: This was a prospective multicenter cohort study of patients using DRV/r under mono or dual therapy plus lamivudine who changed to DRV/c maintaining the previous regimen. All patients had a controlled HIV viral load (<50 copies/ml) when switched and were examined every 12 weeks. The primary end-point was the percentage of participants without virological failure (VF) at week 48 in the intent-to-treat analysis. The CD4 cell count and concentrations of cholesterol, triglyceride, and creatinine were measured from baseline to week 48. RESULTS: A total of 162 patients were included: 68.5% were men, and their mean age was 46 ± 12 years. Seventy (43.2%) patients were treated with DRV/r monotherapy, and 92 (56.8%) were treated with DRV/r plus lamivudine. The efficacy at week 48 was 95.1% (95% CI: 90.6%-97.5%) in the intent-to-treat analysis and 98.7% (95.5-99.6%) in the on-treatment analysis. Two VFs were documented but without development of resistance mutations. No significant changes were found in the lipid profile. Creatinine concentration increased significantly by 0.07 mg/dl (0.04-0.10, P < 0.001). CONCLUSIONS: Switching from DRV/r to DRV/c in patients under mono or dual therapy is safe and effective.es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; JR17/00028es_ES
dc.language.isoenges_ES
dc.publisherTaylor & Francises_ES
dc.relation.urihttps://doi.org/10.1080/15284336.2018.1513974es_ES
dc.rightsThis is an accepted manuscript of an article published by Taylor & Francis in HIV Clinical Trials on 2019, avaliable online in Taylor & Francis Online web page.es_ES
dc.subjectDarunavir/cobicistates_ES
dc.subjectDual therapyes_ES
dc.subjectMonotherapyes_ES
dc.subjectPharmacokineticses_ES
dc.titleDarunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/embargoedAccesses_ES
dc.date.embargoEndDate2020-01-03es_ES
dc.date.embargoLift2020-01-03
UDC.journalTitleHIV Clinical Trialses_ES
UDC.volume19es_ES
UDC.issue5es_ES
UDC.startPage197es_ES
UDC.endPage201es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record